Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OTLK Outlook Therapeutics, Inc.

交易中 02-19 13:34:08 EST

0.4300

+0.0204

+4.98%

最高0.4513	最低0.4120	成交量79.81万
今开0.4125	昨收0.4096	日振幅9.59%
总市值3,161万	流通市值2,502万	总股本7,351万
成交额34.78万	换手率1.37%	流通股本5,818万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.43,"timestamp":1771526044083,"preClose":0.4096,"halted":0,"volume":798057,"delay":0,"changeRate":0.04980468749999993,"floatShares":58175400,"shares":73509500,"eps":-2.349018,"marketStatus":"交易中","change":0.0204,"latestTime":"02-19 13:34:08 EST","open":0.4125,"high":0.4513,"low":0.412,"amount":347800.53484097996,"amplitude":0.095947,"askPrice":0.4365,"askSize":100,"bidPrice":0.43,"bidSize":523,"shortable":3,"etf":0,"ttmEps":-2.349018,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.4096,"preHourTrading":{"tag":"盘前","latestPrice":0.4116,"preClose":0.4096,"latestTime":"09:20 EST","volume":38720,"amount":16391.4196864,"timestamp":1771510814902,"change":0.002,"changeRate":0.004883,"amplitude":0.074951},"postHourTrading":{"tag":"盘后","latestPrice":0.4145,"preClose":0.4096,"latestTime":"18:50 EST","volume":13958,"amount":5748.382635,"timestamp":1771458610852,"change":0.0049,"changeRate":0.011963,"amplitude":0.019287},"volumeRatio":0.621595,"impliedVol":2.2354,"impliedVolPercentile":0.757},"requestUrl":"/m/hq/s/OTLK/tweets","defaultTab":"tweets","newsList":[{"id":"1147633088","title":"Outlook Therapeutics合作推进欧洲商业化战略，Lytenava预计2027年在瑞士上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1147633088","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147633088?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:02","pubTimestamp":1771509746,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.通过合作伙伴关系加速其欧洲市场扩张计划，旗下创新药物Lytenava有望于2027年正式登陆瑞士市场。这一战略部署标志着公司在欧洲商业化布局取得重要进展，为未来业绩增长注入新动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"1178881233","title":"Outlook Therapeutics与Mediconsult Ag达成瑞士独家分销协议 扩大欧洲版图","url":"https://stock-news.laohu8.com/highlight/detail?id=1178881233","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178881233?lang=zh_cn&edition=full","pubTime":"2026-02-19 22:02","pubTimestamp":1771509725,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.宣布与Mediconsult Ag签署独家商业分销协议，将旗下眼科药物Lytenava™（贝伐珠单抗γ）引入瑞士市场。这一战略合作标志着公司在欧洲业务布局的进一步扩展，有望提升其生物类似药产品在欧洲关键市场的可及性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2612978184","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.78%报0.462美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2612978184","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612978184?lang=zh_cn&edition=full","pubTime":"2026-02-17 22:30","pubTimestamp":1771338641,"startTime":"0","endTime":"0","summary":"北京时间2026年02月17日22时30分，Outlook Therapeutics, Inc.股票出现异动，股价快速下挫5.78%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Polaryx Therapeutics, Inc.、Ernexa Therapeutics Inc.、Kalaris Therapeutics, Inc.涨幅较大，Ernexa Therapeutics Inc.、Polaryx Therapeutics, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为60.99%、26.50%、26.09%，振幅较大的相关个股有Alpha Cognition Inc.、Igc Pharma, Inc.、Onconetix, Inc.，振幅分别为10.41%、10.12%、6.97%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc是一家临床阶段生物制药公司，专注于开发和商业化ONS-5010，这是一种用于各种眼科适应症的单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223041a4ad855c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260217223041a4ad855c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","BK4539","BK4007","OTLK"],"gpt_icon":0},{"id":"1145450453","title":"Outlook Therapeutics Inc：拟继续与FDA合作 寻求解决额外验证性证据要求的可行路径","url":"https://stock-news.laohu8.com/highlight/detail?id=1145450453","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145450453?lang=zh_cn&edition=full","pubTime":"2026-02-11 21:50","pubTimestamp":1770817840,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc表示，计划继续与美国食品药品监督管理局（FDA）保持密切合作，共同探索可行路径，以解决FDA提出的关于补充提供额外验证性证据的要求。公司致力于推进相关程序，确保符合监管标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"2603364809","title":"Outlook Therapeutics, Inc.盘中异动 早盘急速下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603364809","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603364809?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:37","pubTimestamp":1768487871,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日22时37分，Outlook Therapeutics, Inc.股票出现异动，股价急速跳水5.11%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，Cns Pharmaceuticals, Inc.、Silexion Therapeutics Corp C/Wts Exp 15/08/2029 、Immunitybio, Inc.涨幅较大，Gt Biopharma, Inc.、Applied Therapeutics, Inc.、Genprex, Inc.较为活跃，换手率分别为50.97%、42.84%、20.56%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 、60 Degrees Pharmaceuticals, Inc.、Cns Pharmaceuticals, Inc.，振幅分别为64.67%、21.43%、15.65%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc是一家临床阶段生物制药公司，专注于开发和商业化ONS-5010，这是一种用于各种眼科适应症的单克隆抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223751a4c81db0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260115223751a4c81db0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","LENZ","BK4007","OTLK"],"gpt_icon":0},{"id":"1141589852","title":"Outlook Therapeutics任命Laura Cantrell为战略规划与业务拓展副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1141589852","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141589852?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:36","pubTimestamp":1767706580,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc.近日宣布一项重要人事任命——Laura Cantrell正式加入公司管理层，担任企业战略与业务发展副总裁一职。此次任命将强化公司在眼科生物制剂领域的战略布局，Cantrell女士将主导全球商业合作机会的挖掘与战略规划体系的优化。首席执行官Russell Trenary表示：\"Laura在生物制药商业拓展领域的卓越履历，与公司现阶段发展需求高度契合。\"据悉，Cantrell将直接向Trenary汇报工作，并参与制定公司长期发展战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1195317623","title":"Outlook Therapeutics公司：FDA尚未明确何种验证性证据可被接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1195317623","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195317623?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:17","pubTimestamp":1767215830,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics公司近日面临监管不确定性，美国食品药品监督管理局（FDA）至今未就公司提交的药品申请给出明确指引。监管机构尚未表态何种类型的验证性临床证据能够满足审批要求，这为该公司核心产品的上市路径增添了变数。\n当前局面反映出生物科技企业在创新药审评过程中常见的挑战。FDA的沉默意味着Outlook Therapeutics需要继续投入资源探索符合监管要求的证据体系，而这一过程可能影响产品商业化的时间表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1145824968","title":"Outlook Therapeutics公布美国FDA对湿性AMD治疗药物Ons-5010/Lytenava™（贝伐珠单抗-Vikg）审评的最新监管进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1145824968","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145824968?lang=zh_cn&edition=full","pubTime":"2026-01-01 05:16","pubTimestamp":1767215790,"startTime":"0","endTime":"0","summary":"生物制药公司Outlook Therapeutics, Inc. (OTLK) 近日披露了旗下核心产品Ons-5010/Lytenava™（贝伐珠单抗-Vikg）针对湿性年龄相关性黄斑变性（湿性AMD）适应症的最新监管动态。该公司已接获美国食品药品监督管理局（FDA）就该项新药申请（BLA）的审评更新通知，标志着该疗法在美获批进程中迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1174726101","title":"Outlook Therapeutics Inc：Ons-5010如获批准，将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1174726101","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174726101?lang=zh_cn&edition=full","pubTime":"2025-11-13 21:31","pubTimestamp":1763040691,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics Inc：Ons-5010如获批准，将以Lytenava品牌用于湿性年龄相关性黄斑变性治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1137059470","title":"FDA拒绝批准眼部疾病药物后，Outlook Therapeutics, Inc.股价盘前暴跌60.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137059470","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137059470?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:35","pubTimestamp":1756377317,"startTime":"0","endTime":"0","summary":"FDA拒绝批准眼部疾病药物后，Outlook Therapeutics, Inc.股价盘前暴跌60.4%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"gpt_icon":0},{"id":"1151455951","title":"Outlook Therapeutics：FDA建议为Ons-5010申请提交确认性疗效证据","url":"https://stock-news.laohu8.com/highlight/detail?id=1151455951","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151455951?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:32","pubTimestamp":1756377134,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics表示，美国食品药品监督管理局(FDA)建议该公司提交确认性疗效证据，以支持其Ons-5010产品的申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"1155673207","title":"Outlook Therapeutics就FDA审查Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性AMD治疗药物提供监管进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1155673207","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155673207?lang=zh_cn&edition=full","pubTime":"2025-08-28 18:30","pubTimestamp":1756377034,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics就美国食品药品监督管理局审查其Ons-5010/Lytenava™(Bevacizumab-Vikg)湿性年龄相关性黄斑变性治疗药物的情况提供了监管进展更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"gpt_icon":0},{"id":"2518042662","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.34%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518042662","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518042662?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:56","pubTimestamp":1741633004,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时56分，Outlook Therapeutics, Inc.股票出现异动，股价急速下跌5.34%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.47%。其相关个股中，Aeon Biopharma, Inc.、Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Biodexa Pharmaceuticals Plc、Scisparc Ltd.较为活跃，换手率分别为6148.90%、3854.04%、1014.79%，振幅较大的相关个股有Aeon Biopharma, Inc.、Protagenic Therapeutics Inc C/Wts 29/04/2026 、Biodexa Pharmaceuticals Plc，振幅分别为90.44%、88.14%、59.34%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025644a26a9d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","OTLK"],"gpt_icon":0},{"id":"2517698565","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大涨5.28%报1.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517698565","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517698565?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:19","pubTimestamp":1741119563,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时19分，Outlook Therapeutics, Inc.股票出现异动，股价急速上涨5.28%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305041923a25f65a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","BK4139","LENZ"],"gpt_icon":0},{"id":"2516688296","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.00%报1.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516688296","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516688296?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:02","pubTimestamp":1741032163,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时02分，Outlook Therapeutics, Inc.股票出现异动，股价大幅跳水5.00%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Biocardia, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4576.31%、211.77%、182.41%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040243abe68edc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","OTLK"],"gpt_icon":0},{"id":"2514566375","title":"Outlook Therapeutics, Inc.盘中异动 早盘快速拉升5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514566375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514566375?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:53","pubTimestamp":1740754380,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时53分，Outlook Therapeutics, Inc.股票出现异动，股价急速上涨5.80%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228225300abe0f06f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","OTLK"],"gpt_icon":0},{"id":"2514045867","title":"Outlook Therapeutics, Inc.盘中异动 下午盘股价大跌5.23%报1.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514045867","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514045867?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:28","pubTimestamp":1740511706,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时28分，Outlook Therapeutics, Inc.股票出现波动，股价急速跳水5.23%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032826abdcc28f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226032826abdcc28f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OTLK","LENZ"],"gpt_icon":0},{"id":"2513214988","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513214988","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513214988?lang=zh_cn&edition=full","pubTime":"2025-02-22 04:07","pubTimestamp":1740168426,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日04时07分，Outlook Therapeutics, Inc.股票出现异动，股价急速下挫5.43%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Invivyd, Inc.、Moolec Science Sa C/Wts 涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为316.92%、251.10%、138.24%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为76.52%、70.25%、61.26%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040707a24ef57e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222040707a24ef57e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OTLK","LENZ","BK4139"],"gpt_icon":0},{"id":"2512166707","title":"Outlook Therapeutics, Inc.盘中异动 股价大跌5.35%报1.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166707","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512166707?lang=zh_cn&edition=full","pubTime":"2025-02-18 23:01","pubTimestamp":1739890874,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时01分，Outlook Therapeutics, Inc.股票出现异动，股价急速下挫5.35%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218230114abd3b5ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218230114abd3b5ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","OTLK","BK4139"],"gpt_icon":0},{"id":"2511257095","title":"Outlook Therapeutics, Inc.盘中异动 临近收盘快速上涨5.17%报1.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511257095","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511257095?lang=zh_cn&edition=full","pubTime":"2025-02-14 04:50","pubTimestamp":1739479816,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日04时50分，Outlook Therapeutics, Inc.股票出现波动，股价急速拉升5.17%。Outlook Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.18%。其相关个股中，Moleculin Biotech, Inc.、Dominari Holdings Inc.、Edesa Biotech, Inc.涨幅较大，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为3288.28%、2317.46%、1269.38%，振幅较大的相关个股有Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为733.31%、95.15%、92.30%。Outlook Therapeutics, Inc.公司简介：Outlook Therapeutics Inc 是一家临床阶段生物制药公司，专注于开发和商业化 ONS-5010，这是一种用于各种眼科适应症的单克隆抗体 。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045016988475bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214045016988475bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","OTLK","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1274},{"period":"1month","weight":-0.2501},{"period":"3month","weight":-0.7821},{"period":"6month","weight":-0.8472},{"period":"1year","weight":-0.7605},{"period":"ytd","weight":-0.7408}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Outlook Therapeutics, Inc.于2010年1月5日在新泽西州注册成立。该公司是一家生物制药公司，在欧盟或欧盟、英国或英国率先获得ONS-5010/LYTENAVA（贝伐珠单抗-gamma）眼科制剂上市许可，用于治疗湿性年龄相关性黄斑变性，或湿性AMD。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.137675},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.049534},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.10242},{"month":5,"riseRate":0.666667,"avgChangeRate":0.154179},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.046947},{"month":7,"riseRate":0.6,"avgChangeRate":0.042124},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Outlook Therapeutics, Inc.(OTLK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}